Monopar Therapeutics (MNPR) Research & Development (2017 - 2026)
Monopar Therapeutics' Research & Development came in at $4.77 million for Q2 2026, up 175.5% from $1.73 million a year earlier.
Powered by 
Analysis
Monopar Therapeutics (MNPR) Research & Development (2017 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Monopar Therapeutics reported Research & Development of $10.73 million, up 8.6% year-over-year; for FY2024, it came in at $8.6 million, up 53.6% from FY2023.
- Research & Development carries a five-year compound annual growth rate of 34.3% (FY2019 to FY2024).
- Going back by year, Research & Development was $5.6 million in FY2023 (-26.2%), $7.59 million in FY2022 (+16.9%), $6.49 million in FY2021 (+59.7%) and $4.07 million in FY2020 (+106.5%).
- The Q2 2026 figure represents the highest quarterly Research & Development since Q4 2024.
- Year-over-year, Research & Development increased in five of the last six quarters, with growth averaging 144.9%.
- The fastest year-over-year change in Research & Development over five years came in Q4 2024 (growth of 432.9%), and the weakest in Q4 2023 (a decline of 50.8%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Monopar Therapeutics | 635.73 Mn | 353.96 Mn | - | 4.77 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.77 Mn |
| Sep 30, 2025 | 2.59 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 1.64 Mn |
| Dec 31, 2024 | 5.52 Mn |
| Sep 30, 2024 | 984,278.00 |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 966,110.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.59 Mn |
| Mar 31, 2023 | 1.65 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 1.73 Mn |
| Jun 30, 2022 | 2.08 Mn |
| Mar 31, 2022 | 1.68 Mn |
| Dec 31, 2021 | 1.98 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 1.48 Mn |
| Mar 31, 2021 | 1.21 Mn |
API Access
Monopar Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MNPR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MNPR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MNPR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();